ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

In Brief: Dickersin Named To NCAB; Gallo To Retire; FASEB Suggests 10% Increase For NIH

January 20, 1995

Adjuvant Chemo Improves Survival In Early Lung Cancer

July 30, 2004

In Brief: Cancer Program Bill Renews Congressional Commitment To Principles, Rep. Carter Says

May 5, 1978

Obituaries: Fritz Bach, 77, and William Wolff, 94

September 9, 2011

Clinical Trials Approved In August 2002 By NCI

September 27, 2002

Prevention Program Being Developed For Primary Providers

January 29, 1988